345 related articles for article (PubMed ID: 29939889)
21. Evaluation of Aspirin Prescribing and Gastrointestinal Bleeding in Adults 60 Years of Age and Older in a Large, Academic Health System.
Potthast KL; Billups SJ; Fixen DR; Titus O; Saseen JJ; Linnebur SA
Sr Care Pharm; 2024 Jun; 39(6):218-227. PubMed ID: 38803024
[No Abstract] [Full Text] [Related]
22. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.
Selak V; Elley CR; Crengle S; Harwood M; Doughty R; Arroll B; Bryant L; Rafter N; Hoorn SV; Wadham A; Wells S; Milne R; Jackson R; Bramley D; Rodgers A
Contemp Clin Trials; 2011 Nov; 32(6):909-15. PubMed ID: 21777702
[TBL] [Abstract][Full Text] [Related]
23. Aspirin for primary prevention: yes or no?
Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
[TBL] [Abstract][Full Text] [Related]
24. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.
Burkholder GA; Tamhane AR; Salinas JL; Mugavero MJ; Raper JL; Westfall AO; Saag MS; Willig JH
Clin Infect Dis; 2012 Dec; 55(11):1550-7. PubMed ID: 22942209
[TBL] [Abstract][Full Text] [Related]
25. Compliance with USPSTF recommendations on aspirin for prevention of cardiovascular disease in men.
Malayala SV; Raza A
Int J Clin Pract; 2016 Nov; 70(11):898-906. PubMed ID: 27619938
[TBL] [Abstract][Full Text] [Related]
26. Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?
Fiscella K; Winters PC; Mendoza M; Noronha GJ; Swanger CM; Bisognano JD; Fortuna RJ
J Gen Intern Med; 2015 Feb; 30(2):155-60. PubMed ID: 25092016
[TBL] [Abstract][Full Text] [Related]
27. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review.
Bem D; Dretzke J; Stevens S; Lordkipanidzé M; Hodgkinson J; Bayliss S; Moore D; Fitzmaurice D
Syst Rev; 2015 Jun; 4():88. PubMed ID: 26088608
[TBL] [Abstract][Full Text] [Related]
28. Aspirin and Cancer.
Patrignani P; Patrono C
J Am Coll Cardiol; 2016 Aug; 68(9):967-76. PubMed ID: 27561771
[TBL] [Abstract][Full Text] [Related]
29. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
Mora S; Manson JE
JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
[TBL] [Abstract][Full Text] [Related]
30. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force.
Dehmer SP; O'Keefe LR; Evans CV; Guirguis-Blake JM; Perdue LA; Maciosek MV
JAMA; 2022 Apr; 327(16):1598-1607. PubMed ID: 35471506
[TBL] [Abstract][Full Text] [Related]
31. Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis.
Selak V; Jackson R; Poppe K; Wu B; Harwood M; Grey C; Pylypchuk R; Mehta S; Choi YH; Kerr A; Wells S
Ann Intern Med; 2019 Oct; 171(8):529-539. PubMed ID: 31525775
[TBL] [Abstract][Full Text] [Related]
32. Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease.
Dempster DW; Rosenstock JL; Schwimmer JA; Panagopoulos G; DeVita MV; Michelis MF
Clin Nephrol; 2005 Nov; 64(5):371-7. PubMed ID: 16312265
[TBL] [Abstract][Full Text] [Related]
33. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
Whitlock EP; Burda BU; Williams SB; Guirguis-Blake JM; Evans CV
Ann Intern Med; 2016 Jun; 164(12):826-35. PubMed ID: 27064261
[TBL] [Abstract][Full Text] [Related]
34. Impact of updated recommendations on acetylsalicylic acid use for primary prevention of cardiovascular disease in Canada: a population-based survey.
Khalili M; Lepeytre F; Guertin JR; Goupil R; Troyanov S; Bouchard J; Madore F
CMAJ Open; 2020; 8(1):E41-E47. PubMed ID: 31992558
[TBL] [Abstract][Full Text] [Related]
35. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
[TBL] [Abstract][Full Text] [Related]
36. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?
Leggio M; Bendini MG; Caldarone E; Lombardi M; Severi P; D'Emidio S; Stavri DC; Armeni M; Bravi V; Mazza A
Diabetes Metab; 2018 Jun; 44(3):217-225. PubMed ID: 29257747
[TBL] [Abstract][Full Text] [Related]
37. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer.
Puhan MA; Yu T; Stegeman I; Varadhan R; Singh S; Boyd CM
BMC Med; 2015 Oct; 13():250. PubMed ID: 26423305
[TBL] [Abstract][Full Text] [Related]
38. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
